secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2024-12-03T23:59:59+00:00
Accession:  0001628280-24-049669
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen releases presentation with clinical data showing treatment benefit in retinal disease studies
--------------------------------------------------------------------------------

- Presentation shows mean change in total atrophy area from baseline reduced by 84% in treated group (0.12 mm²) vs untreated (0.73 mm²).
- Visual acuity improvement in treated eyes across multiple cohorts (006-001, 007-001, 006-004) compared to untreated.
- Treated mutant group shows better outcomes than untreated mutant in LL VA change over 6 months.
- Presentation posted on company website December 3, 2024 and may be used in investor discussions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828024049669/0001628280-24-049669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828024049669/ocgn-20241203.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-049669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer